Journal for ImmunoTherapy of Cancer

Contentshow all

    • Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

      p. 1

Cite

Citation style:
Could not load citation form.

Rights

Use and reproduction:
All rights reserved